Ferguson Enterprises (NYSE:FERG) Stock

Ferguson Enterprises

Ferguson

Ferguson distributes plumbing and HVAC products to North American repair, maintenance and improvement, new construction, and civil infrastructure markets. It serves over 1 million customers and sources products from 36,000 suppliers. Ferguson engages customers through approximately 1,800 North American branches, over the phone, online, and in residential showrooms. According to Modern Distribution Management, Ferguson is the largest plumbing distributor and second-largest HVAC distributor (next to Watsco) in North America. The firm sold its UK business in 2021 and is now solely focused on the North American market.

Ferguson Enterprises Inc

First Quantum Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FM#TSX">FM</a>) reported quarterly sales of $1.19 billion which beat the analyst consensus estimate of $1.06 billion by 12.26 percent. This is a 14.86 percent increase over sales of $1.04 billion the same period last year.

Earnings

Earnings Beats

News

TSX:FM

First Quantum Minerals Q1 Sales $1.19B Beat $1.06B Estimate

<a href="https://www.bloomberg.com/news/articles/2025-04-23/trump-orders-truck-import-probe-setting-stage-for-us-tariffs">https://www.bloomberg.com/news/articles/2025-04-23/trump-orders-truck-import-probe-setting-stage-for-us-tariffs</a>

General

'Trump Orders Truck Import Probe, Setting Stage for US Tariffs'- Bloomberg

Ensysce Biosciences, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) stock gained almost 100% with a strong session volume compared to the average volume of 81.23K, as <a target="_blank" href="https://www.benzinga.com/pro/feature/newsfeed" rel="noreferrer noopener">per data from Benzinga Pro</a>.
Ensysce Biosciences on Wednesday received a Notice of Allowance from the U.S. Patent and Trademark Office for the issuance of a patent entitled&nbsp;Enzyme-Cleavable Methadone Prodrugs and Methods of Use Thereof including both composition of matter and <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">method of use claims</a>.
PF9001, the medication covered by this patent, is designed to provide a safer treatment option for opioid use disorder (OUD) by using Ensysce&#8217;s TAAP&nbsp;and MPAR&nbsp;abuse-deterrent and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/ac44946545/ensysce-biosciences-receives-u-s-patent-for-groundbreaking-treatment-of-opioid-use-disorder" rel="noreferrer noopener">overdose protection technologies</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44963467/why-is-summit-therapeutics-stock-soaring-on-wednesday" rel="noreferrer noopener">Why Is Summit Therapeutics Stock Soaring On Wednesday?</a>
Methadone has long been used for OUD, but concerns over cardiac side effects, respiratory depression, and risk of overdose have limited its use.
Ensysce has developed a new class of agents for OUD in the form of PF9001.
Data demonstrating a reduction in the potential for cardiotoxicity, validating MPAR&nbsp;overdose protection, and indications of potentially delivering a prolonged and predictable effect following once-daily dosing.
The National Institute on Drug Abuse of the National Institutes of Health supported the research covered by this patent.
Ensysce Biosciences completed Part 1 of its second clinical trial in April to evaluate PF614-MPAR <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/ac44810577/ensysce-biosciences-announces-positive-data-from-opioid-overdose-protection-study" rel="noreferrer noopener">for overdose protection</a>.
PF614-MPAR-102 demonstrated that the combined Ensysce TAAP&nbsp;and MPAR&nbsp;technologies can relieve severe pain yet protect from the risk of excessive doses when consumed accidentally or deliberately.
Part 1 of this second study of PF614-MPAR overdose protection confirmed that a 100 mg dosage of PF614-MPAR delivers oxycodone to treat severe pain and provides overdose protection when a greater-than-prescribed dose is consumed.
The data showed that the maximum amount of oxycodone released from PF614-MPAR, when three or more doses were taken at one time (Cmax), was reduced compared to that released following the consumption of the same amount of PF614 alone, evidence of overdose protection.
When five doses of PF614-MPAR were administered, overdose protection was appropriately greater than that observed from three dose units.
Additionally, safety data from the trial showed no unexpected adverse events from either PF614 or PF614-MPAR.
The trial will now continue to enroll Part 2 to examine potential food effects and Part 3 to evaluate repeat dosing of PF614 vs. PF614-MPAR. The aggregate data will allow the company to focus on perfecting a final drug product to move into commercialization.
Ensysce Biosciences announced approximately $1.1 million of registered direct offering in March by issuing 315,188 shares <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/ac44559449/ensysce-biosciences-inc-announces-1-1-million-registered-direct-offering-priced-at-the-market-und" rel="noreferrer noopener">at $3.49 per share</a>.
Price Action: ENSC stock is up 96.30% at $3.67 on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/25/04/44963523/rezolute-thrilled-with-positive-review-of-genetic-disorder-trial-expects-topline-results-in-december" target="_blank" rel="noreferrer noopener">Rezolute &#8216;Thrilled&#8217; With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December</a></li>
</ul>
Photo by Gorodenkoff via Shutterstock

Biotech

Health Care

Movers

Trading Ideas

ENSC

Ensysce Biosciences Stock Doubles In One Trading Session - Here's Why

Texas Instruments Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>) reported first-quarter financial results after the market close on Wednesday. Here&#8217;s a look at the key metrics <a href="https://www.benzinga.com/quote/TXN">from the quarter</a>.
<ul>
<li>Q1 Revenue: $4.07 billion, versus <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $3.91 billion</li>
</ul>
<ul>
<li>Q1 EPS: $1.28, versus estimates of $1.07</li>
</ul>
Total revenue climbed 11% year-over-year and 2% sequentially as all markets saw a quarter-over-quarter increase with the exception of personal electronics, which the company attributed to seasonality.
Texas Instruments reported $6.2 billion in cash flow from operations over the trailing 12 months, and $1.7 billion of free cash flow over the same period. 
&#8220;History says it is important to have capacity and inventory in times like these, and we are well positioned,&#8221; the company said on a conference call with investors. 
&#8220;In addition, geopolitically dependable capacity will matter more, and it is increasingly critical and valuable to our customers. We have flexibility and are prepared to navigate the evolving supply chain dynamics.&#8221;
Related Link: <a href="https://www.benzinga.com/news/earnings/25/04/44966124/ibm-shares-slide-despite-better-than-expected-q1-details">IBM Shares Slide Despite Better-Than-Expected Q1: Details</a>
Outlook: Texas Instruments sees second-quarter revenue of $4.17 billion to $4.53 billion versus estimates of $4.13 billion. The company expects second-quarter earnings to be between $1.21 and $1.47 per share versus estimates of $1.23 per share. 
Texas Instruments noted on the conference call that it doesn&#8217;t expect any near-term impacts related to macroeconomic uncertainty. But, the company will take a cautious approach as there are &#8220;many things still changing.&#8221; Texas Instruments said it&#8217;s working with customers to understand and support their needs and is prepared for a &#8220;range of scenarios&#8221; in the second half of the year, heading into 2026.
TXN Price Action: <a href="http://benzinga.com/quote/txn">Texas Instruments shares</a> were up after-hours 5.15% at $159.99 at the time of publication on Wednesday, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: michelmond/Shutterstock.

Guidance

After-Hours Center

Tech

Texas Instruments Q1 Earnings: Revenue Beat, EPS Beat, Strong Guidance — 'Prepared To Navigate The Evolving Supply Chain Dynamics'

NewMarket (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEU#NYSE">NEU</a>) reported quarterly earnings of $13.26 per share. This is a 18.08 percent increase over earnings of $11.23 per share from the same period last year. The company reported $700.95 million in sales this quarter. This is a 0.60 percent increase over sales of $696.74 million the same period last year.

NewMarket Q1 EPS $13.26 Up From $11.23 YoY, Sales $700.95M Up From $696.74M YoY

<h3>Gainers</h3>
<ul>
<li>Wag Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PET#NASDAQ">PET</a>) shares increased by 58.6% to $0.17 during Wednesday's after-market session. The market value of their outstanding shares is at $8.8 million. </li>
<li>Linkage Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCB#NASDAQ">LGCB</a>) shares rose 26.7% to $2.42. The company's market cap stands at $7.4 million. </li>
<li>QVC Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QVCGA#NASDAQ">QVCGA</a>) shares increased by 11.86% to $0.17. The market value of their outstanding shares is at $67.6 million. </li>
<li>ZHONGCHAO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZCMD#NASDAQ">ZCMD</a>) shares increased by 10.18% to $1.19. The company's market cap stands at $30.0 million. </li>
<li>REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) stock moved upwards by 8.15% to $2.85. The company's market cap stands at $80.0 million. </li>
<li>Epsium Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EPSM#NASDAQ">EPSM</a>) shares increased by 7.8% to $5.8. The market value of their outstanding shares is at $76.8 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares declined by 8.2% to $0.42 during Wednesday's after-market session. The company's market cap stands at $6.7 million. </li>
<li>Jack In The Box (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JACK#NASDAQ">JACK</a>) shares declined by 6.57% to $23.75. The market value of their outstanding shares is at $447.8 million. </li>
<li>Bloomin Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>) stock decreased by 5.89% to $7.92. The market value of their outstanding shares is at $672.6 million. </li>
<li>Springview Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) shares fell 5.04% to $0.45. The company's market cap stands at $5.1 million. </li>
<li>Worksport (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) shares declined by 4.92% to $2.71. The company's market cap stands at $12.9 million. </li>
<li>Top Win International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOPW#NASDAQ">TOPW</a>) shares declined by 4.88% to $2.66. The company's market cap stands at $66.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLMN

EPSM

JACK

LGCB

QVCGA

SPHL

TOPW

WKSP

ZCMD

12 Consumer Discretionary Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Community Health Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CYH#NYSE">CYH</a>) shares rose 13.2% to $2.75 during Wednesday's after-market session. The company's market cap stands at $382.0 million. As per the press release, Q1 earnings came out today. </li>
<li>Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) stock increased by 11.55% to $5.31. The company's market cap stands at $250.8 million. </li>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) stock increased by 8.61% to $0.35. The company's market cap stands at $25.0 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock moved upwards by 7.6% to $0.28. The company's market cap stands at $73.8 million. </li>
<li>Vanda Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) stock increased by 7.18% to $4.64. The market value of their outstanding shares is at $270.6 million. </li>
<li>Clearside Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSD#NASDAQ">CLSD</a>) shares rose 6.83% to $0.85. The company's market cap stands at $65.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Relmada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLMD#NASDAQ">RLMD</a>) shares declined by 20.4% to $0.54 during Wednesday's after-market session. The market value of their outstanding shares is at $17.8 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares decreased by 19.62% to $2.95. The company's market cap stands at $4.1 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock fell 9.33% to $0.61. The market value of their outstanding shares is at $43.4 million. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares fell 8.03% to $7.34. The company's market cap stands at $347.8 million. </li>
<li>60 Degrees (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTP#NASDAQ">SXTP</a>) shares fell 6.98% to $2.8. The market value of their outstanding shares is at $4.1 million. </li>
<li>INVO Fertility (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) stock decreased by 6.12% to $1.8. The company's market cap stands at $8.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAP

CADL

CLSD

CTOR

NAYA

OVID

RLMD

SXTP

VNDA

ZYBT

12 Health Care Stocks Moving In Wednesday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>FBS Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBGL#NASDAQ">FBGL</a>) stock increased by 23.6% to $0.91 during Wednesday's after-market session. The company's market cap stands at $12.2 million. </li>
<li>Ideal Power (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPWR#NASDAQ">IPWR</a>) stock moved upwards by 6.73% to $5.55. The market value of their outstanding shares is at $46.2 million. </li>
<li>American Rebel Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AREB#NASDAQ">AREB</a>) stock moved upwards by 5.85% to $3.25. The market value of their outstanding shares is at $7.6 million. </li>
<li>Click Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLIK#NASDAQ">CLIK</a>) shares rose 5.35% to $0.25. The market value of their outstanding shares is at $7.9 million. </li>
<li>SKYX Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYX#NASDAQ">SKYX</a>) stock moved upwards by 5.0% to $1.05. The company's market cap stands at $109.6 million. </li>
<li>Proficient Auto Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAL#NASDAQ">PAL</a>) shares increased by 4.84% to $8.66. The market value of their outstanding shares is at $234.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Robert Half (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) shares decreased by 13.9% to $40.0 during Wednesday's after-market session. The market value of their outstanding shares is at $4.0 billion. As per the press release, Q1 earnings came out today. </li>
<li>Jayud Global Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JYD#NASDAQ">JYD</a>) stock decreased by 8.78% to $0.24. The market value of their outstanding shares is at $23.1 million. </li>
<li>Multi Ways Holdings (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MWG#AMEX">MWG</a>) stock fell 7.26% to $0.27. The company's market cap stands at $8.9 million. </li>
<li>Primega Group Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) shares decreased by 6.85% to $0.45. The company's market cap stands at $11.8 million. </li>
<li>Flux Power Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLUX#NASDAQ">FLUX</a>) stock declined by 4.71% to $1.62. The company's market cap stands at $27.1 million. </li>
<li>CleanCore Solutions (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ZONE#AMEX">ZONE</a>) shares decreased by 4.7% to $1.21. The company's market cap stands at $9.6 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AREB

CLIK

FBGL

FLUX

IPWR

PGHL

SKYX

ZONE

12 Industrials Stocks Moving In Wednesday's After-Market Session

Fastenal Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) ('Fastenal', the 'Company', 'we', 'our', or 'us') announced today that its board of directors approved a two-for-one stock split of the Company's outstanding common stock to be effected through an amendment to the Company's Restated Articles of Incorporation (the 'Amendment'). The Amendment will also effect a proportionate increase in the number of shares of authorized common stock.
Holders of record of the Company's common stock at the close of business on May 5, 2025 will receive one additional share of common stock for every share of common stock they own. The stock split will take effect at the close of business on May 21, 2025, and trading is expected to begin on a split-adjusted basis on or about May 22, 2025.

Stock Split

FAST

Fastenal Company Announces 2-For-1 Stock Split. Expected To Begin On A Split-Adjusted Basis On Or About May 22, 2025

<h3>Gainers</h3>
<ul>
<li>Impinj (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) shares rose 14.2% to $88.0 during Wednesday's after-market session. The market value of their outstanding shares is at $2.5 billion. The company's, Q1 earnings came out today. </li>
<li>ServiceNow (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) stock moved upwards by 9.63% to $890.99. The company's market cap stands at $183.9 billion. As per the press release, Q1 earnings came out today. </li>
<li>Fatpipe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FATN#NASDAQ">FATN</a>) stock increased by 7.61% to $12.43. The company's market cap stands at $170.5 million. </li>
<li>E2open Parent Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETWO#NYSE">ETWO</a>) shares increased by 6.73% to $2.22. The market value of their outstanding shares is at $686.7 million. </li>
<li>BitFuFu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) stock moved upwards by 5.44% to $4.19. The market value of their outstanding shares is at $681.9 million. </li>
<li>Rimini Street (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RMNI#NASDAQ">RMNI</a>) shares increased by 5.31% to $3.27. The company's market cap stands at $297.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ostin Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares decreased by 5.3% to $1.98 during Wednesday's after-market session. The market value of their outstanding shares is at $72.3 million. </li>
<li>IBM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBM#NYSE">IBM</a>) stock fell 4.94% to $233.36. The company's market cap stands at $216.3 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Sonim Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SONM#NASDAQ">SONM</a>) stock decreased by 4.73% to $1.41. The company's market cap stands at $6.8 million. </li>
<li>Peraso (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRSO#NASDAQ">PRSO</a>) stock decreased by 4.64% to $0.8. The company's market cap stands at $3.0 million. </li>
<li>Mobilicom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOB#NASDAQ">MOB</a>) shares decreased by 4.63% to $1.65. The company's market cap stands at $12.3 million. </li>
<li>Syntec Optics Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTX#NASDAQ">OPTX</a>) stock declined by 4.2% to $1.37. The market value of their outstanding shares is at $50.2 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ETWO

FATN

FUFU

OPTX

PRSO

RMNI

SONM

12 Information Technology Stocks Moving In Wednesday's After-Market Session

—Largest Global Clinical Trial Ever Conducted in Bronchiectasis Demonstrates Statistically Significant and Clinically Meaningful Reduction in Frequency of Pulmonary Exacerbations Versus Placebo—
—Brensocatib 25 mg is the First Investigational Therapy for Bronchiectasis to Show a Statistically Significant Reduction in the Rate of Lung Function Decline—
—Brensocatib is Currently Under Priority Review with the U.S. Food and Drug Administration—
BRIDGEWATER, N.J., April 23, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that positive results from the pivotal phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis were published in the New England Journal of Medicine (NEJM). The landmark ASPEN study is the largest clinical trial ever conducted in bronchiectasis, a serious, chronic, and progressive inflammatory pulmonary disease that today has no approved therapies.

INSM

Insmed Announces New England Journal Of Medicine Publishes Results From Its Pivotal Phase 3 ASPEN Study Of Brensocatib In Patients With Bronchiectasis; Largest Global Clinical Trial Ever Conducted In Bronchiectasis Demonstrates Statistically Significant And Clinically Meaningful Reduction In Frequency Of Pulmonary Exacerbations Versus Placebo

South Plains Financial (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPFI#NASDAQ">SPFI</a>) will release its quarterly earnings report on Thursday, 2025-04-24. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate South Plains Financial to report an earnings per share (EPS) of $0.67.
South Plains Financial bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings History Snapshot</h3>
In the previous earnings release, the company beat EPS by $0.28, leading to a 0.0% drop in the share price the following trading session.
Here's a look at South Plains Financial's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.68</td>
<td>0.66</td>
<td>0.58</td>
<td>0.57</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.96</td>
<td>0.66</td>
<td>0.66</td>
<td>0.64</td>
</tr>
<tr>
<td>Price Change %</td>
<td>5.0%</td>
<td>-1.0%</td>
<td>1.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745442213_0.png" alt="eps graph" />
<h3>Tracking South Plains Financial's Stock Performance</h3>
Shares of South Plains Financial were trading at $32.94 as of April 22. Over the last 52-week period, shares are up 24.55%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/SPFI/earnings">To track all earnings releases for South Plains Financial visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SPFI

South Plains Financial Earnings Preview

Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) is set to give its latest quarterly earnings report on Thursday, 2025-04-24. Here's what investors need to know before the announcement.
Analysts estimate that Faro Technologies will report an earnings per share (EPS) of $0.09. 
The market awaits Faro Technologies's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.10, which was followed by a 17.33% increase in the share price the next day.
Here's a look at Faro Technologies's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.4</td>
<td>0.03</td>
<td>0.01</td>
<td>-0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.5</td>
<td>0.21</td>
<td>0.18</td>
<td>0.09</td>
</tr>
<tr>
<td>Price Change %</td>
<td>17.0%</td>
<td>36.0%</td>
<td>5.0%</td>
<td>-3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745442198_0.png" alt="eps graph" />
<h3>Performance of Faro Technologies Shares</h3>
Shares of Faro Technologies were trading at $24.09 as of April 22. Over the last 52-week period, shares are up 43.09%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<h3>Analyst Observations about Faro Technologies</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Faro Technologies.
Analysts have provided Faro Technologies with 1 ratings, resulting in a consensus rating of Buy. The average one-year price target stands at $37.0, suggesting a potential 53.59% upside.
<h3>Analyzing Ratings Among Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of Red Cat Hldgs, PowerFleet and Ouster, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Red Cat Hldgs, with an average 1-year price target of $13.0, suggesting a potential 46.04% downside.</li>
<li>Analysts currently favor an Outperform trajectory for PowerFleet, with an average 1-year price target of $13.4, suggesting a potential 44.38% downside.</li>
<li>Analysts currently favor an Outperform trajectory for Ouster, with an average 1-year price target of $14.67, suggesting a potential 39.1% downside.</li>
</ul>
<h3>Analysis Summary for Peers</h3>
Within the peer analysis summary, vital metrics for Red Cat Hldgs, PowerFleet and Ouster are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Faro Technologies</td>
<td>Buy</td>
<td>-5.37%</td>
<td>$53.08M</td>
<td>-0.39%</td>
</tr>
<tr>
<td>Red Cat Hldgs</td>
<td>Outperform</td>
<td>-60.96%</td>
<td>$-23.48K</td>
<td>-44.83%</td>
</tr>
<tr>
<td>PowerFleet</td>
<td>Outperform</td>
<td>207.14%</td>
<td>$58.78M</td>
<td>-3.16%</td>
</tr>
<tr>
<td>Ouster</td>
<td>Outperform</td>
<td>23.11%</td>
<td>$13.18M</td>
<td>-13.46%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Faro Technologies ranks at the top for Revenue Growth and Gross Profit among its peers. However, it ranks at the bottom for Return on Equity.
<h3>Unveiling the Story Behind Faro Technologies</h3>
Faro Technologies Inc is a technology company. It designs, develops, manufactures, markets and supports software-driven, three-dimensional (3-D) measurement, imaging, and realization solutions for the 3D metrology, architecture, engineering and construction (AEC), Operations and Maintenance (O&amp;M) and public safety analytics markets. The company enables its customers to capture, measure, manipulate, interact with and share 3D and 2D data from the physical world in a virtual environment and then translate the information back into the physical domain. FARO suite of 3D products and software solutions are used for the inspection of components and assemblies, rapid prototyping, reverse engineering, documenting large volumes or structures in 3D, surveying, and construction.
<h3>Understanding the Numbers: Faro Technologies's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Decline in Revenue: Over the 3 months period, Faro Technologies faced challenges, resulting in a decline of approximately -5.37% in revenue growth as of 31 December, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Faro Technologies's net margin excels beyond industry benchmarks, reaching -1.05%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -0.39%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Faro Technologies's ROA excels beyond industry benchmarks, reaching -0.2%. This signifies efficient management of assets and strong financial health.
Debt Management: Faro Technologies's debt-to-equity ratio is below the industry average. With a ratio of 0.36, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<a href="https://www.benzinga.com/quote/FARO/earnings">To track all earnings releases for Faro Technologies visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

FARO

A Look Ahead: Faro Technologies's Earnings Forecast

Customers Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBI#NYSE">CUBI</a>) will release its quarterly earnings report on Thursday, 2025-04-24. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Customers Bancorp to report an earnings per share (EPS) of $1.30.
The market awaits Customers Bancorp's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.16, leading to a 13.9% increase in the share price on the subsequent day.
Here's a look at Customers Bancorp's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.20</td>
<td>1.43</td>
<td>1.43</td>
<td>1.63</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.36</td>
<td>1.34</td>
<td>1.49</td>
<td>1.42</td>
</tr>
<tr>
<td>Price Change %</td>
<td>14.000000000000002%</td>
<td>-1.0%</td>
<td>4.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745442190_0.png" alt="eps graph" />
<h3>Performance of Customers Bancorp Shares</h3>
Shares of Customers Bancorp were trading at $46.26 as of April 22. Over the last 52-week period, shares are down 2.16%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/CUBI/earnings">To track all earnings releases for Customers Bancorp visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CUBI

Insights Ahead: Customers Bancorp's Quarterly Earnings

Hilltop Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HTH#NYSE">HTH</a>) will release its quarterly earnings report on Thursday, 2025-04-24. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Hilltop Hldgs to report an earnings per share (EPS) of $0.27.
The announcement from Hilltop Hldgs is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings Track Record</h3>
In the previous earnings release, the company beat EPS by $0.27, leading to a 1.28% increase in the share price the following trading session.
Here's a look at Hilltop Hldgs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.28</td>
<td>0.37</td>
<td>0.26</td>
<td>0.25</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.55</td>
<td>0.46</td>
<td>0.31</td>
<td>0.42</td>
</tr>
<tr>
<td>Price Change %</td>
<td>1.0%</td>
<td>-1.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745442175_0.png" alt="eps graph" />
<h3>Tracking Hilltop Hldgs's Stock Performance</h3>
Shares of Hilltop Hldgs were trading at $28.78 as of April 22. Over the last 52-week period, shares are down 4.68%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/HTH/earnings">To track all earnings releases for Hilltop Hldgs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Hilltop Hldgs

Preliminary First Quarter 2025 Results
For the first quarter of 2025, Total Revenue, Land Agreement Proceeds and Interest&#x2A; was $3.6 million (revenue of $3.1 million), equating to 1,249 gold equivalent ounces ("GEOs")&#x2A;. Royalty, stream, pre-production, and loan interest all increased in 2025, while land agreement proceeds decreased by $1.5 million due to higher one-time payments in the first quarter of 2024. Further growth in revenue is expected through 2025 driven by strong commodity prices supporting the Company's cash flowing royalties at Canadian Malartic, Côté, Borborema, Cozamin and Borden (Porcupine) and the Vareš&nbsp;copper stream.
Gold Royalty maintains its 2025 full-year production guidance 5,700 - 7,000 GEOs as released on March 20, 2025, and expects that production will be more heavily weighted to the second half of the year as recently-started mining operations including Côté, Vareš, and Borborema continue to ramp up towards full production run rates through 2025.
&#x2A;GEOs and Total Revenue, Land Agreement Proceeds and Interest are non-IFRS financial measures. See "Non-IFRS Measures" below.

GROY

Gold Royalty Announces Q1 2025 Preliminary Results; Total Revenue, Land Agreement Proceeds And Interest Was $3.6M (Revenue Of $3.1M), Equating To 1,249 Gold Equivalent Ounces; Maintains Its 2025 Full-Year Production Guidance 5,700 - 7,000 GEOs

Apollo Comml Real Est (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARI#NYSE">ARI</a>) is set to give its latest quarterly earnings report on Thursday, 2025-04-24. Here's what investors need to know before the announcement.
Analysts estimate that Apollo Comml Real Est will report an earnings per share (EPS) of $0.22. 
Anticipation surrounds Apollo Comml Real Est's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.10, which was followed by a 9.9% increase in the share price the next day.
Here's a look at Apollo Comml Real Est's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.22</td>
<td>0.26</td>
<td>0.30</td>
<td>0.30</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.32</td>
<td>0.31</td>
<td>0.35</td>
<td>0.35</td>
</tr>
<tr>
<td>Price Change %</td>
<td>10.0%</td>
<td>-0.0%</td>
<td>-1.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745442165_0.png" alt="eps graph" />
<h3>Market Performance of Apollo Comml Real Est's Stock</h3>
Shares of Apollo Comml Real Est were trading at $8.63 as of April 22. Over the last 52-week period, shares are down 15.28%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/ARI/earnings">To track all earnings releases for Apollo Comml Real Est visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look at Apollo Comml Real Est's Upcoming Earnings Report

Management

ADGM

Adagio Medical Holdings Appointed Daniel George As Interim CFO On April 17, 2025

Indivior (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) is set to give its latest quarterly earnings report on Thursday, 2025-04-24. Here's what investors need to know before the announcement.
Analysts estimate that Indivior will report an earnings per share (EPS) of $0.23. 
Anticipation surrounds Indivior's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.06, leading to a 6.01% drop in the share price on the subsequent day.
Here's a look at Indivior's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.26</td>
<td>0.36</td>
<td>0.14</td>
<td>0.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.32</td>
<td>0.54</td>
<td>0.44</td>
<td>0.37</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>3.0%</td>
<td>-2.0%</td>
<td>2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1745442156_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Indivior were trading at $8.81 as of April 22. Over the last 52-week period, shares are down 45.22%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/INDV/earnings">To track all earnings releases for Indivior visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

INDV

A Look at Indivior's Upcoming Earnings Report

Oceaneering International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.29 by 48.28 percent. This is a 207.14 percent increase over earnings of $0.14 per share from the same period last year. The company reported quarterly sales of $674.52 million which beat the analyst consensus estimate of $651.30 million by 3.56 percent. This is a 12.59 percent increase over sales of $599.09 million the same period last year.

Oceaneering International Q1 Adj. EPS $0.43 Beats $0.29 Estimate, Sales $674.52M Beat $651.30M Estimate

Commodities

Press Releases

PERENfra announces Perennial Infrastructure Fund I

Ferguson to Issue Second Quarter Results And Host Conference Call on March 11, 2025

Comments

Ferguson Enterprises

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL